Biotechs rise and fall on the science and not on the activities of the BOD and data and results will determine success or failure.not who is running or managing the company..
With all due respect Footmax I put those comments of yours in the same bin as Ziors shares on issue don't matter..silly and dangerous thinking..
If that were the case maybe one could expand on that and say anyone with a great product or fantastic new invention for that matter is guaranteed success..sadly that's not the case..
The product needs to be well managed to get it threw to the profitable stage where its owners...in Imugenes case its shareholders can reef the financial benfits..
An example of miss management which is a real possibility for imugene is the inability to raise the nessary capital to progress the trials..In particular the battle between raising capital vs delayed results because of unforeseen issues/Nature of the beast..
There would be many examples where miss management of a product by management has caused catastrophic failure to a business success
If Lesile management skills were ill relevant to Imugenes success i doubt she would be commanding 2.5mil as a base salary..
My opinion is at this stage of Imugenes journey hopper is now a problem when we look at his past history of how and who he has in his network for raising capital he now appears to be skating on thin ice..
If punters think 8billion shares on issue is a lot now jst wait and see how many may eventuate if lesile has to manange threw it if trial result delays continue as they have done so in the past..
Again with all due respect footmax good management is crucial and no one will ever convince me otherwise bio or other..
Dyor..just my opinion and never advice
IMU Price at posting:
3.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)